Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Kim, Ju Yeon ^a   Han, Wonshik ^b   Moon, Hyeong Gon ^b   Ahn, Soo K ^b   Kim, Jisun ^b   Lee, Jun W ^b   Kim, Min K ^b   Kim, Taeryung ^c   Noh, Dong Young ^b  

^a Gyeongsang National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Gachon University   (South Korea)

Author keywords

Estradiol; Metastasis; Postmenopause; Survival

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; FOLLITROPIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; DISTANT METASTASIS; DRUG SUBSTITUTION; ESTRADIOL BLOOD LEVEL; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD; METASTASIS FREE SURVIVAL; POSTMENOPAUSE; PREOPERATIVE EVALUATION; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; POSTMENOPAUSE; PREOPERATIVE PERIOD; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR BURDEN;

EID: 84886147713     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-503     Document Type: Article

References (24)

1. Cummings SR, Lee JS, Lui LY, Stone K, Ljung BM, Cauleys JA. Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidemiol Biomarkers Prev 2005, 14:1047-1051. 10.1158/1055-9965.EPI-04-0375, 15894651.
2. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002, 17:606-616.
3. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 2009, 18:384-398.
4. Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, et al. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 2009, 18:169-176. 10.1158/1055-9965.EPI-08-0808, 19124495.
5. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004, 15:1856-1865.
6. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005, 12:1071-1082. 10.1677/erc.1.01038, 16322344.
7. Rock CL, Flatt SW, Laughlin GA, Gold EB, Thomson CA, Natarajan L, et al. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:614-620. 10.1158/1055-9965.EPI-07-0761, 2575111, 18323413.
8. Berrino F, Pasanisi P, Bellati C, Venturelli E, Krogh V, Mastroianni A, et al. Serum testosterone levels and breast cancer recurrence. Int J Cancer 2005, 113:499-502. 10.1002/ijc.20582, 15455345.
9. Secreto G, Zumoff B. Paradoxical effects associated with supranormal urinary testosterone excretion in premenopausal women with breast cancer: increased risk of postmastectomy recurrence and higher remission rate after ovariectomy. Cancer Res 1983, 43:3408-3411.
10. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993, 15:17-35.
11. Hulka BS. Epidemiology of susceptibility to breast cancer. Prog Clin Biol Res 1996, 395:159-174.
12. Pathak DR, Osuch JR, He J. Breast carcinoma etiology: current knowledge and new insights into the effects of reproductive and hormonal risk factors in black and white populations. Cancer 2000, 1(5 Suppl):1230-1238.
13. Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer 2000, 7:73-83. 10.1677/erc.0.0070073, 10903525.
14. Haakensen VD, Bjoro T, Luders T, Riis M, Bukholm IK, Kristensen VN, et al. Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas. BMC cancer 2011, 11:332. 10.1186/1471-2407-11-332, 3163631, 21812955.
15. Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2000, 2:335-344. 10.1186/bcr78, 138655, 11250726.
16. Gupta PB, Kuperwasser C. Contributions of estrogen to ER-negative breast tumor growth. J Steroid Biochem Mol Biol 2006, 102:71-78. 10.1016/j.jsbmb.2006.09.025, 17049443.
17. Banka CL, Lund CV, Nguyen MT, Pakchoian AJ, Mueller BM, Eliceiri BP. Estrogen induces lung metastasis through a host compartment-specific response. Cancer Res 2006, 1:3667-3672.
18. Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA, et al. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res 2007, 1:2062-2071.
19. Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992, 11:71-85. Early Breast Cancer Trialists' Collaborative Group.
20. Nissen-Meyer R. Prophylactic endocrine treatment in carcinoma of the breast. Clin Radiol 1964, 15:152-160. 10.1016/S0009-9260(64)80031-3, 14140852.
21. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 23:1616-1622.
22. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009, 101:80-87. 10.1093/jnci/djn442, 2639318, 19141781.
23. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005, 23:7491-7496. 10.1200/JCO.2004.00.7138, 16234515.
24. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007, 25:3846-3852. 10.1200/JCO.2007.11.9453, 17679725.